Phenotype-driven cascade screening in a Syrian family with clinically consistent multiple endocrine neoplasia type 2A Authors: Munawar Hraib, Mona Alturun, Taim Al Kheder, Faozat Alonainy Published: 2026 ABSTRACT AbstractMultiple endocrine neoplasia type 2A (MEN2A) is an autosomal dominant hereditary endocrine tumor syndrome classically associated with medullary thyroid carcinoma (MTC), pheochromocytoma, and primary hyperparathyroidism. Early recognition is important because cascade screening may identify affected relatives before advanced disease develops. We report a Syrian family with a clinically MEN2A-consistent phenotype. The index patient, a 37-year-old male, presented with a large multinodular thyroid mass and was found to have markedly elevated plasma metanephrines, bilateral adrenal masses, and elevated serum calcitonin and carcinoembryonic antigen. He underwent bilateral adrenalectomy followed by total thyroidectomy with bilateral neck dissection. Histopathology confirmed bilateral pheochromocytoma and multifocal MTC with gross extrathyroidal extension and lateral cervical lymph-node metastasis. Phenotype-driven cascade screening identified a 39-year-old sister with elevated calcitonin, metanephrine, and normetanephrine levels, bilateral adrenal masses, bilateral pheochromocytoma, and MTC, representing a second first-degree relative with the MEN2A-defining combination of MTC and bilateral pheochromocytoma. A 26-year-old brother was found to have synchronous papillary thyroid carcinoma and oncocytic/Hürthle-cell carcinoma with negative calcitonin immunostaining. This family highlights the value of phenotype-driven cascade screening when rearranged during transfection (RET) proto-oncogene testing is unavailable and emphasizes the importance of precise pathological classification of nonmedullary thyroid tumors in individuals from MEN2A-consistent families.Keywords: MEN2A, medullary thyroid carcinoma, pheochromocytoma, cascade screening, RET proto-oncogene, papillary thyroid carcinoma Introduction Multiple endocrine neoplasia type 2 (MEN2) is a rare autosomal dominant hereditary endocrine tumor syndrome caused by germline pathogenic variants in the rearranged during transfection (RET) proto-oncogene. The syndrome comprises 2 distinct clinical entities, MEN2A and MEN2B, with MEN2A accounting for ∼95% of cases. MEN2A has an estimated prevalence of 13 to 24 per million individuals and is classically characterized by medullary thyroid carcinoma (MTC), pheochromocytoma, and primary hyperparathyroidism, whereas MEN2B is considerably rarer, with a prevalence of 1 to 2 per million, and is associated with MTC, pheochromocytoma, mucosal and intestinal ganglioneuromatosis, and characteristic musculoskeletal and ophthalmologic abnormalities. Early recognition is clinically important because MTC may be the first manifestation of the syndrome, while unrecognized pheochromocytoma may lead to serious perioperative cardiovascular complications [1-5]. Once MEN2 is suspected, biochemical evaluation for pheochromocytoma and systematic cascade screening of first-degree relatives are essential [1,4,5]. RET testing is the preferred method for confirming the hereditary diagnosis and guiding family screening when available [1,4]. Throughout this paper, we describe a clinically MEN2A-consistent Syrian family in which RET testing was unavailable. Case presentation A 37-year-old Syrian male, with no known prior medical history, no history of smoking, and no alcohol consumption, presented with swelling on the right side of the neck associated with dyspnea. He denied fever, weight loss, episodic headache, palpitations, sweating, or symptoms suggestive of paroxysmal hypertension. There was no history of electrolyte disturbance or previously diagnosed endocrine disease. Family history was notable for clustering of endocrine tumors predominantly on the paternal side. Several paternal cousins had pathology-confirmed endocrine tumors, including MTC and/or pheochromocytoma. One cousin had both MTC and bilateral pheochromocytoma. The pedigree is shown in Fig. 1. Pedigree of an MEN2A-consistent Syrian family. The pedigree demonstrates clustering of MTC and pheochromocytoma predominantly on the paternal side of the family, supporting a hereditary MEN2-spectrum disorder. The proband (arrow) and his sister were both diagnosed with the MEN2A-defining combination of MTC and bilateral pheochromocytoma. Additional paternal cousins had pathology-confirmed MTC, pheochromocytoma, or both, further strengthening the evidence for familial disease aggregation. No maternal history of endocrine neoplasia was reported, and there was no history of consanguinity. The father did not undergo systematic evaluation because of financial constraints, whereas the paternal uncles could not be systematically evaluated because of loss of direct contact with the proband; therefore, their disease status is designated as unknown. Phenotype-driven cascade screening of first-degree relatives following diagnosis of the proband identified an affected sister with the same tumor combination, whereas a brother was found to have synchronous PTC and oncocytic/Hürthle-cell carcinoma without evidence of medullary differentiation. The apparent concentration of endocrine neoplasms among paternal relatives and the absence of reported maternal-side disease are consistent with autosomal dominant inheritance, although definitive genetic confirmation was not possible because germline rearranged during transfection (RET) proto-oncogene testing was unavailable locally. This pedigree served as the foundation for targeted family screening and clinical diagnosis in the absence of molecular testing. Diagnostic assessment Physical examination revealed a large right-sided neck mass. Baseline laboratory investigations are summarized in Table 1. Biochemical evaluation demonstrated markedly elevated serum calcitonin, carcinoembryonic antigen (CEA), and plasma free metanephrine and normetanephrine concentrations, raising suspicion for MTC and catecholamine-secreting adrenal disease. Table 1Biochemical, hormonal, and tumor marker findings at presentation and 3-month post-operation follow-up in the index patientParameterLabs at presentationLabs at 3-month follow-upReference rangeCalcitonin877 pg/mL(256.6 pmol/L)680 pg/mL(198.9 pmol/L)<20 pg/mL(<5.85 pmol/L)CEA90 ng/mL(90 µg/L)76 ng/mL(76 µg/L)<5 ng/mL(<5 µg/L)Plasma free metanephrine1221 pg/mL(6190 pmol/L)520 pg/mL(2636 pmol/L)<90 pg/mL(<456.3 pmol/L)Plasma free normetanephrine2093 pg/mL(11 427 pmol/L)4200 pg/mL(22 932 pmol/L)<180 pg/mL(<982.8 pmol/L)TSH1.35 mIU/L(1.35 mIU/L)1.6 mIU/L(1.6 mIU/L)0.27-5.0 mIU/L(0.27-5.0 mIU/L)Free T41.24 ng/dL(15.96 pmol/L)1.3 ng/dL(16.73 pmol/L)0.93-1.72 ng/dL(11.97-22.14 pmol/L)Calcium9 mg/dL(2.25 mmol/L)8.6 mg/dL(2.15 mmol/L)8.5-10.5 mg/dL(2.13-2.63 mmol/L)Phosphorus4.4 mg/dL(1.42 mmol/L)4.7 mg/dL(1.52 mmol/L)2.6-4.9 mg/dL(0.84-1.58 mmol/L)PTH111.7 pg/mL(111.7 ng/L)22 pg/mL(22 ng/L)10-70 pg/mL(10-70 ng/L)25-Hydroxyvitamin D13.96 ng/mL(34.8 nmol/L)24 ng/mL(59.9 nmol/L)30-50 ng/mL(74.9-124.8 nmol/L)Labs were measured under conventional units and converted to SI units in parentheses for manuscript data presentation.Abbreviations: CEA, carcinoembryonic antigen; PTH, parathyroid hormone; T4, thyroxine; TSH, thyroid-stimulating hormone. Biochemical, hormonal, and tumor marker findings at presentation and 3-month post-operation follow-up in the index patient Labs were measured under conventional units and converted to SI units in parentheses for manuscript data presentation. Abbreviations: CEA, carcinoembryonic antigen; PTH, parathyroid hormone; T4, thyroxine; TSH, thyroid-stimulating hormone. Contrast-enhanced computed tomography (CT) of the neck, chest, abdomen, and pelvis demonstrated a multinodular thyroid mass with cervical lymphadenopathy and bilateral adrenal masses (Fig. 2A). Despite markedly elevated catecholamine metabolites and large adrenal tumors, the patient had no documented symptoms of catecholamine excess. Thyroid function was normal, with no biochemical evidence of primary hyperparathyroidism. Clinical pathway of the index patient and outcomes of phenotype-driven cascade screening. The figure illustrates the diagnostic, therapeutic, and follow-up course of the index patient and the subsequent family-based evaluation prompted by a clinically suspected MEN2A phenotype. The index patient presented with a thyroid mass and markedly elevated calcitonin, CEA, and catecholamine metabolites. Computed tomography demonstrated a multinodular thyroid mass with cervical lymphadenopathy and bilateral adrenal masses (A). Following preoperative α-adrenergic blockade, he underwent bilateral adrenalectomy followed by total thyroidectomy with bilateral neck dissection, with histopathology confirming bilateral pheochromocytoma and multifocal MTC. At follow-up, persistent locoregional disease was considered currently unresectable and was associated with life-threatening respiratory symptoms, prompting initiation of cabozantinib therapy; the feasibility of further surgical intervention remains under consideration. Phenotype-driven cascade screening was initiated after recognition of the index patient's MEN2A-consistent phenotype. Because germline rearranged during transfection (RET) proto-oncogene testing was unavailable, available first-degree relatives underwent targeted biochemical evaluation and cross-sectional imaging, with histopathological confirmation of detected lesions where applicable. This approach identified a sister with the MEN2A-defining combination of MTC and bilateral pheochromocytoma, providing strong clinical support for a hereditary MEN2A-spectrum disorder (B). In contrast, screening of a brother revealed synchronous PTC and oncocytic/Hürthle-cell carcinoma without biochemical, radiologic, or pathological evidence of MTC or pheochromocytoma, underscoring the importance of careful pathological classification of thyroid neoplasms detected during screening of high-risk families (C). The combination of a thyroid mass, elevated calcitonin and CEA, biochemical evidence of catecholamine excess, bilateral adrenal tumors, and pathology-confirmed endocrine neoplasia in multiple paternal cousins strongly suggested MEN2A. However, because germline RET testing was unavailable, diagnosis relied on the characteristic clinical phenotype and the reported family history in paternal cousins rather than molecular confirmation (Fig. 2A). Treatment Given the biochemical and radiological evidence of bilateral pheochromocytoma, the patient underwent standard preoperative α-adrenergic blockade and volume expansion, followed by bilateral adrenalectomy and lifelong corticosteroid replacement therapy (Fig. 2A). Histopathological examination confirmed bilateral pheochromocytoma with high cellularity, cellular spindling, nuclear pleomorphism, and a pheochromocytoma of the adrenal gland scaled score (PASS) of 7 (Fig. 3). Immunohistochemistry demonstrated diffuse chromogranin and synaptophysin positivity with S100-positive sustentacular cells, confirming the diagnosis. Histopathological findings in the index patient. (A) Medullary thyroid carcinoma showing infiltrative nests of neoplastic cells embedded within abundant eosinophilic stromal amyloid (hematoxylin and eosin stain; original magnification ×100). (B) Low-power view of pheochromocytoma demonstrating the characteristic nested (Zellballen) growth pattern (hematoxylin and eosin stain; original magnification ×40). (C) Higher-power view of pheochromocytoma showing polygonal tumor cells with abundant granular eosinophilic cytoplasm and round to oval nuclei (hematoxylin and eosin stain; original magnification ×400). After recovery, total thyroidectomy with bilateral neck dissection and removal of three and a half parathyroid glands was performed (Fig. 2A). Histopathology demonstrated multifocal MTC with marked extrathyroidal extension, angioinvasion, amyloid deposition, and metastatic involvement of the lateral cervical lymph nodes. Clinical staging showed no evidence of distant metastasis, corresponding to tumor–node–metastasis classification pT4a pN1b cM0 (Fig. 3). Outcome and follow-up Three months after surgery, biochemical reassessment demonstrated persistent elevation of calcitonin, CEA, and plasma free normetanephrine levels (Table 1). Follow-up CT imaging showed persistent thyroid-bed lesions, residual cervical lymphadenopathy, bilateral adrenal-bed lesions, and a retroperitoneal lesion, consistent with persistent disease (Fig. 2A). Given the locally advanced, currently unresectable persistent MTC associated with life-threatening respiratory symptoms, systemic therapy with cabozantinib was initiated, while the feasibility of further surgical intervention remains under consideration. The patient remains under close biochemical and radiological surveillance. Phenotype-driven cascade screening of first-degree relatives is summarized in Fig. 2B and 2C. The patient's 39-year-old sister was found to have the MEN2A-defining combination of MTC and bilateral pheochromocytoma, confirmed histopathologically after surgery. The 26-year-old brother had thyroid nodules but normal calcitonin and catecholamine metabolite levels. Histopathology after total thyroidectomy demonstrated synchronous PTC and oncocytic/Hürthle-cell carcinoma with negative calcitonin immunostaining, supporting a nonmedullary origin of both tumors (Fig. 4). He subsequently received radioactive iodine therapy and remains under surveillance. Histopathological findings in the brother's thyroidectomy specimen. (A) Papillary thyroid carcinoma showing characteristic nuclear features, including nuclear enlargement, chromatin clearing, nuclear overlapping, and nuclear grooves (hematoxylin and eosin stain; original magnification ×400). (B) Oncocytic/Hürthle-cell carcinoma composed of follicular cells with abundant granular eosinophilic cytoplasm (hematoxylin and eosin stain; original magnification ×100). (C) Negative calcitonin immunostaining, supporting the absence of medullary differentiation (calcitonin immunohistochemistry; original magnification ×100). Discussion This family demonstrates a highly MEN2A-consistent phenotype despite the absence of molecular confirmation. Both the index patient and his 39-year-old sister had the MEN2A-defining combination of MTC and bilateral pheochromocytoma, while several paternal relatives had pathology-confirmed MTC and/or pheochromocytoma. Together, these findings strongly support a hereditary MEN2A-spectrum disorder. However, because germline RET testing was unavailable locally in Syria, the family should be regarded as having an MEN2A-consistent phenotype rather than genetically confirmed MEN2A [1-5]. The index patient's presentation is clinically important because he harbored large bilateral pheochromocytomas despite lacking classic adrenergic symptoms. MEN2A-associated pheochromocytomas may be clinically subtle, and absence of characteristic symptoms does not exclude the diagnosis. Because unrecognized pheochromocytoma may result in serious perioperative complications, current recommendations emphasize biochemical evaluation and treatment before thyroid surgery in suspected MEN2A. Accordingly, bilateral adrenalectomy was performed before thyroidectomy in this case [4,5]. The most important finding in this report emerged through phenotype-driven cascade screening. The index patient's sister was found to have elevated calcitonin, metanephrine, and normetanephrine concentrations, bilateral adrenal masses, and thyroid nodules. Histopathological examination subsequently confirmed bilateral pheochromocytoma and MTC, establishing her as a second first-degree relative with the MEN2A-defining tumor combination. This finding reinforces the value of family-based screening, particularly in resource-limited settings where molecular testing may not be available. Ideally, screening should incorporate germline RET testing together with biochemical and imaging evaluation. However, when RET testing cannot be obtained, phenotype-driven screening remains clinically justified and may facilitate identification of affected relatives before advanced disease develops [1,4]. The brother's findings require separate interpretation. As a first-degree relative within a MEN2A-consistent family, he remains clinically at risk and would ideally undergo germline RET testing. Nevertheless, his pathological findings do not support MTC. Instead, he was found to have synchronous PTC and oncocytic/Hürthle-cell carcinoma, both of which are follicular-cell-derived thyroid malignancies. Importantly, calcitonin immunostaining was negative, arguing against medullary differentiation. Accordingly, these tumors should not be interpreted as calcitonin-negative MTC. Rather, the most appropriate interpretation is synchronous non-MTCs detected during family screening, while his MEN2 genetic status remains unresolved because molecular testing was unavailable [4,6,7]. Sporadic or environmental contributors to the brother's follicular-cell-derived thyroid malignancies cannot be excluded. Although previous ionizing-radiation exposure is an established risk factor for PTC, no relevant exposure was identified in this patient, and no etiological inference can be made from the available data. Accordingly, the PTC and oncocytic/Hürthle-cell carcinoma are interpreted as synchronous nonmedullary thyroid malignancies of uncertain etiology rather than established manifestations of MEN2A. The coexistence of PTC with MEN2A or MTC has been reported but remains uncommon and should not be considered a defining manifestation of MEN2A. In a study of 135 MEN2 patients, only 2 cases of PTC without accompanying C-cell pathology were identified, highlighting the rarity of this association and the limited evidence supporting a biological relationship. When MTC and PTC coexist, prognosis and management are generally driven by the MTC component [8-11]. The oncocytic/Hürthle-cell carcinoma identified in the brother should be interpreted even more cautiously. Hürthle-cell carcinoma is a follicular-cell-derived malignancy and is not recognized as part of the MEN2 tumor spectrum. Although isolated reports have documented synchronous Hürthle-cell carcinoma and MTC, these observations demonstrate coexistence of distinct thyroid malignancies rather than evidence that Hürthle-cell carcinoma represents a MEN2-associated lesion. In addition, rare oncocytic variants of MTC may mimic follicular-cell-derived oncocytic tumors morphologically, making immunohistochemistry particularly important. In the present case, negative calcitonin immunostaining strongly supported a nonmedullary origin and excluded oncocytic MTC [6,7,12,13]. A recent case report described MEN2A in association with PTC and other follicular-cell-derived thyroid tumors. However, the authors emphasized that it remains unclear whether these tumors are causally related to RET variants or merely coincidental. This is relevant to the present case because, although the brother may theoretically be a RET carrier, his PTC and oncocytic/Hürthle-cell carcinoma do not themselves establish MEN2A [14]. The pedigree further supports paternal familial aggregation, with several pathology-confirmed endocrine neoplasms among paternal relatives. However, the disease status of the father and paternal uncles remains unknown because they did not undergo systematic biochemical, imaging, or genetic evaluation. Given the variable penetrance and age-dependent expression of MEN2, the exact inheritance pattern cannot be confirmed in the absence of molecular testing [1,4]. The principal limitation of this report is the absence of germline RET testing, which prevented definitive molecular confirmation, genotype-specific risk stratification, and genotype-guided counseling of relatives. An additional limitation is that the father and paternal uncles could not undergo biochemical, radiological, or genetic evaluation because of financial constraints and the lack of regular contact with the proband and his immediate family. Consequently, their disease status remains unknown, and the exact pattern of familial segregation could not be fully characterized. A further limitation of this report relates to the extent of parathyroid surgery. Current guidelines recommend that parathyroid surgery in MEN2A be reserved for patients with biochemically confirmed primary hyperparathyroidism, with resection directed toward abnormal glands. In retrospect, subtotal parathyroidectomy in this normocalcemic patient without confirmed primary hyperparathyroidism would not be considered guideline-concordant management. Despite these limitations, this experience illustrates how careful phenotypic assessment and family-based screening can guide clinical decision-making when genetic testing is inaccessible, especially in a resource-limited context and low-income countries. Ultimately, germline RET testing remains the preferred method for confirming MEN2 and screening at-risk relatives because it identifies clinically unaffected carriers, enables genotype-specific risk stratification, and guides the timing of preventive thyroidectomy. The phenotype-driven approach used in this family was an interim strategy necessitated by the local unavailability of RET testing and should not be interpreted as an equivalent alternative to molecular testing. The proband, his siblings, his children, and the offspring of other clinically affected family members require genetic counseling and germline RET testing as soon as this becomes accessible. Testing should preferably begin in an affected family member, followed by variant-specific testing of at-risk relatives if a pathogenic germline variant is identified. Learning points MEN2A may present with clinically silent pheochromocytoma; absence of classic adrenergic symptoms does not exclude the diagnosis. MEN2A may present with clinically silent pheochromocytoma; absence of classic adrenergic symptoms does not exclude the diagnosis. In suspected MEN2A, pheochromocytoma should be biochemically evaluated and treated before thyroid surgery to reduce the risk of perioperative complications. In suspected MEN2A, pheochromocytoma should be biochemically evaluated and treated before thyroid surgery to reduce the risk of perioperative complications. Phenotype-driven cascade screening can facilitate identification of affected relatives with MEN2A-associated tumors when germline RET testing is unavailable; however, phenotype-driven biochemical and imaging surveillance is an interim approach only when molecular testing is inaccessible. Phenotype-driven cascade screening can facilitate identification of affected relatives with MEN2A-associated tumors when germline RET testing is unavailable; however, phenotype-driven biochemical and imaging surveillance is an interim approach only when molecular testing is inaccessible. Non-MTCs detected during screening of MEN2A-consistent families should not be automatically attributed to MEN2; careful pathological classification and immunohistochemical evaluation remain essential. Non-MTCs detected during screening of MEN2A-consistent families should not be automatically attributed to MEN2; careful pathological classification and immunohistochemical evaluation remain essential. Contributors All authors made individual contributions to authorship. M.H.: study conception and design; clinical diagnosis and management; manuscript writing. M.A.: clinical diagnosis and management. T.A.K.: clinical diagnosis; development of the phenotype-driven family assessment; manuscript writing. F.A.: clinical diagnosis and management; senior clinical and scientific oversight. All authors reviewed and approved the final draft. Abbreviations carcinoembryonic antigen computed tomography multiple endocrine neoplasia type 2 multiple endocrine neoplasia type 2A medullary thyroid carcinoma Pheochromocytoma of the Adrenal gland Scaled Score papillary thyroid carcinoma parathyroid hormone rearranged during transfection proto-oncogene Contributor Information Munawar Hraib, Department of Oncology, Al-Bairuni University Hospital, Damascus, Syria; Faculty of Medicine, Damascus University, Damascus, Syria. Mona Alturun, Department of Oncology, Al-Bairuni University Hospital, Damascus, Syria; Faculty of Medicine, Damascus University, Damascus, Syria. Taim Al Kheder, Faculty of Medicine, Damascus University, Damascus, Syria. Faozat Alonainy, Department of Oncology, Al-Bairuni University Hospital, Damascus, Syria. Funding No public or commercial funding. Disclosures None declared. Informed patient consent for publication Signed informed consent obtained directly from the patients. Data availability All relevant clinical data are included in this article. Data sharing is not applicable to this article, as no datasets were generated or analyzed during the current study. References Associated Data Data Availability Statement All relevant clinical data are included in this article. Data sharing is not applicable to this article, as no datasets were generated or analyzed during the current study.